MoonLake Immunotherapeutics (NASDAQ:MLTX) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of class A ordinary shares and pre-funded warrants Made bigger: about US$200M · US$20 a share · Leerink Partners +5 Dealers: Leerink Partners (co-lead), Guggenheim Securities (co-lead), Cantor (co-lead), LifeSci Capital (co-lead), H.C. Wainwright & Co., Clear Street Use of proceeds: Research, development, pre-commercialization and commercialization of sonelokimab, if approved, and general corporate purposes | Jun 24, 2026 |
| Public offering of class A ordinary shares Announced: about US$75M · US$10.5 a share · Leerink Partners Dealers: Leerink Partners (lead) Use of proceeds: To fund research and development of sonelokimab and for general corporate purposes | Nov 5, 2025 |